What is Robocath?
Founded in 2009 by Dr. Philippe Bencteux, Robocath designs, develops, and commercializes robotic systems aimed at enhancing the safety and efficacy of treatments for cardiovascular diseases. Its flagship product, the R-One system, utilizes advanced technology to optimize precision in robotic-assisted coronary angioplasty, a critical procedure performed globally every 30 seconds. The R-One system's open architecture ensures compatibility with existing market-leading devices and cath labs, facilitating its integration into clinical workflows. The system has demonstrated strong clinical performance, achieving 100% technical success and no major adverse cardiovascular events in pre-clinical trials. Having received CE marking in February 2019 and commencing clinical application in September 2019, Robocath's technology is currently available in Europe and Africa, with ambitions to lead the global vascular robotics market and pioneer remote treatment for vascular emergencies.
How much funding has Robocath raised?
Robocath has raised a total of $56.3M across 3 funding rounds:
Series A
$7.6M
Series B
$5.3M
Series C
$43.4M
Series A (2017): $7.6M with participation from Normandie Participations, GO Capital, M Capital Advisors, Cardio Participation, and Groupe Credit Agricole
Series B (2019): $5.3M led by NCI, Normandie Participations, M Capital, Go Capital, and Supernova Invest
Series C (2020): $43.4M supported by TUS-Holdings, Anaxago, Zhejiang Silk Road Fund, CS Group, and MicroPort Scientific Corporation
Key Investors in Robocath
NCI
NCI is a prominent regional private equity firm that invests in businesses across various stages, with a focus on supporting SMEs and startups in northwestern France. They are known for their commitment to sustainable economic development.
Go Capital
GEOC, a China-Israel fund, invests in Israeli high-tech companies across life sciences, digital technologies, and AI, aiming to facilitate market penetration and strategic partnerships in China.
Supernova Invest
Supernova Invest provides expertise and capital to deeptech leaders in industrial technologies, digital, healthcare, and cleantech, supporting high-growth startups with a focus on ESG principles.
What's next for Robocath?
With its latest major strategic investment, Robocath is poised to accelerate its expansion and solidify its position as a leader in vascular robotics. The substantial capital infusion is expected to fuel further research and development, enhance manufacturing capabilities, and broaden the global commercial reach of its R-One system. The company's focus on improving patient outcomes and making advanced medical procedures more accessible aligns with the growing demand for innovative healthcare solutions. Robocath's strategic vision to become the world leader in vascular robotics, coupled with its commitment to developing remote treatment capabilities, positions it for significant future growth and impact in the medical technology landscape.
See full Robocath company page
